EMC to Assume Costs of Tumor Analysis for Employees and Relatives With Cancer

SCHWALBACH, Germany and HEIDELBERG, Germany, Sept. 23, 2015 (GLOBE NEWSWIRE) -- As of September 1, 2015, EMC in Germany will be joining forces with Molecular Health to launch a Corporate Oncology Program for Employees (COPE). If an EMC employee or the spouse, partner, or child of an EMC employee are diagnosed with cancer, the program will fund an analysis of the patient's tumor genome so that the most promising treatment options can be identified.

"Every day we spend many intense hours working together. No one is left unmoved when they hear that cancer has touched the life of a colleague or a colleague's family member," says Sabine Bendiek, managing director of EMC Germany, about the new program. Gabriele Schickel, the director of human resources at EMC, adds, "We asked ourselves what we as an employer could do in situations like these. We offer a great deal to healthy employees. But how can we support colleagues who get sick?" The answer for EMC Germany employees and their families is COPE. EMC, an IT company with headquarters near Boston, Massachusetts (USA), employs some 70,000 people around the world; its main German office is located in Schwalbach am Taunus.

EMC is Molecular Health's second COPE customer. "There's been a lot of interest in COPE over the past few months. Typically it is forward-thinking companies like EMC that make special efforts to look after their employees," said Lutz Voelker, CEO of Molecular Health.

Part of the COPE program involves Molecular Health's TreatmentMAP™: the tool analyzes and interprets the tumor genome and the ways in which it differs from healthy tissue in a clinical context. TreatmentMAP compares patient-specific genetic information with the latest international biomedical knowledge. This allows treating physicians to manage the incredibly complex masses of data so they can match the tumor profile to a suitable treatment. As a result, they can identify the therapeutic option with the highest potential benefit while also avoiding side effects as much as possible. Confidentiality is a natural component of our process. The patient remains anonymous. All patient-relevant data remains confidential and is never given to third parties or the employer.

MOLECULAR HEALTH is a leading biomedical company which transforms molecular data into actionable clinical information, identifying the most efficacious and safest cancer treatment options for each individual cancer patient. TreatmentMAP is the first registered medical device of its kind in Europe for precision cancer medicine. Molecular Health GmbH has been audited and certified in accordance with ISO 13485 for the design, development, and production of software systems which perform integrated analyses of clinical and genetic patient data to support treatment decisions and offer related services. For more information, see: www.molecularhealth.com;


EMC Corporation enables companies and service providers to transform their business processes and offer IT-as-a-service. Cloud computing is a key factor in this transformation. EMC offers innovative products and services to assist IT departments into the cloud. Thanks to EMC solutions, information, as the most important asset can be saved, managed, protected, and prepared for analysis -- flexibly, securely, and cost-efficiently. Further information about EMC can be found at: http://www.emc.com

CONTACT: Press contact Molecular Health GmbH EU: Carla Mertens +49 (0)6221 43851-2275 carla.mertens@molecularhealth.com North America: Mark Rodgers: +1-832-247-3068 mark.rodgers@molecularhealth.com EMC Deutschland GmbH Christian Viermann +49 (0)61 96 47 28 - 639 christian.viermann@emc.com Public Relations Manager

Source:Molecular Health